Interleukin-6 contributes to inflammation and remodeling in a model of Adenosine mediated lung injury

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Pedroza, Mesias ^a,b   Schneider, Daniel J ^a,b   Karmouty Quintana, Harry ^a   Coote, Julie ^c   Shaw, Stevan ^c   Corrigan, Rebecca ^a,b   Molina, Jose G ^a   Alcorn, Joseph L ^a,b   Galas, David ^d   Gelinas, Richard ^d   Blackburn, Michael R ^a,b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UCB PHARMA   (Belgium)

^d INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ADENOSINE DEAMINASE; INTERLEUKIN 6; STAT3 PROTEIN; NEUTRALIZING ANTIBODY;

AIRWAY REMODELING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; DISEASE COURSE; LUNG ALVEOLUS EPITHELIUM; LUNG FIBROSIS; LUNG INJURY; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PNEUMONIA; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; ANIMAL; DISEASE MODEL; EPITHELIUM CELL; FEMALE; GENE INACTIVATION; GENETICS; IMMUNOLOGY; LUNG ALVEOLUS; MALE; METABOLISM; PATHOLOGY;

ANIMALIA; MUS;

ADENOSINE; ADENOSINE DEAMINASE; ANIMALS; ANTIBODIES, NEUTRALIZING; DISEASE MODELS, ANIMAL; EPITHELIAL CELLS; FEMALE; GENE KNOCKOUT TECHNIQUES; INTERLEUKIN-6; LUNG INJURY; MALE; MICE; PNEUMONIA; PULMONARY ALVEOLI; PULMONARY FIBROSIS; STAT3 TRANSCRIPTION FACTOR;

EID: 79960740114     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022667     Document Type: Article

References (59)

1. Thannickal VJ, Toews GB, White ES, Lynch JP 3rd, Martinez FJ, (2004) Mechanisms of pulmonary fibrosis. Annu Rev Med 55: 395-417.
2. Vestbo J, Prescott E, (1997) Update on the "Dutch hypothesis" for chronic respiratory disease. Lancet 350: 1431-1434.
3. Sime PJ, O'Reilly KM, (2001) Fibrosis of the lung and other tissues: new concepts in pathogenesis and treatment. Clin Immunol 99: 308-319.
4. Kung HC, Hoyert DL, Xu J, Murphy SL, (2008) Deaths: final data for 2005. Natl Vital Stat Rep 56: 1-120.
5. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, et al. (2007) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 176: 532-555 Epub 2007 May 2016.
6. Fredholm BB, (2007) Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death Differ 14: 1315-1323.
7. Hasko G, Nemeth ZH, Vizi ES, Salzman AL, Szabo C, (1998) An agonist of adenosine A3 receptors decreases interleukin-12 and interferon-gamma production and prevents lethality in endotoxemic mice. Eur J Pharmacol 358: 261-268.
8. Chan ES, Cronstein BN Adenosine in fibrosis. Mod Rheumatol 20: 114-122.
9. Zhou Y, Schneider DJ, Blackburn MR, (2009) Adenosine signaling and the regulation of chronic lung disease. Pharmacol Ther 123: 105-116.
10. Driver AG, Kukoly CA, Ali S, Mustafa SJ, (1993) Adenosine in bronchoalveolar lavage fluid in asthma. Am Rev Respir Dis 148: 91-97.
11. Blackburn MR, Chun GL, Young HWJ, Chunn JL, Banerjee SK, et al. (2003) Adenosine mediates IL-13-induced inflammation and remodeling in the lung: evidence for an IL-13-adenosine amplification pathway. J Clin Invest 112: 332-344.
12. Fredholm BB, AP IJ, Jacobson KA, Klotz KN, Linden J, (2001) International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 53: 527-552.
13. Chunn JL, Young HW, Banerjee SK, Colasurdo GN, Blackburn MR, (2001) Adenosine-dependent airway inflammation and hyperresponsiveness in partially adenosine deaminase-deficient mice. J Immunol 167: 4676-4685.
14. Varani K, Caramori G, Vincenzi F, Adcock I, Casolari P, et al. (2006) Alteration of adenosine receptors in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 173: 398-406.
15. Zhou Y, Murthy JN, Zeng D, Belardinelli L, Blackburn MR, (2010) Alterations in adenosine metabolism and signaling in patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. PLoS One 5: e9224.
16. Sun CX, Zhong H, Mohsenin A, Morschl E, Chunn JL, et al. (2006) Role of A2B receptor signaling in adenosine-dependent pulmonary inflammation and injury. J Clin Invest 116: 1-10.
17. Zhong H, Belardinelli L, Maa T, Zeng D, (2005) Synergy between A2B Adenosine Receptors and Hypoxia in Activating Human Lung Fibroblasts. Am J Respir Cell Mol Biol 32: 2-8.
18. Doganci A, Sauer K, Karwot R, Finotto S, (2005) Pathological role of IL-6 in the experimental allergic bronchial asthma in mice. Clin Rev Allergy Immunol 28: 257-270.
19. Eddahibi S, Chaouat A, Tu L, Chouaid C, Weitzenblum E, et al. (2006) Interleukin-6 gene polymorphism confers susceptibility to pulmonary hypertension in chronic obstructive pulmonary disease. Proc Am Thorac Soc 3: 475-476.
20. Pantelidis P, Fanning GC, Wells AU, Welsh KI, Du Bois RM, (2001) Analysis of tumor necrosis factor-alpha, lymphotoxin-alpha, tumor necrosis factor receptor II, and interleukin-6 polymorphisms in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 163: 1432-1436.
21. Saito F, Tasaka S, Inoue K, Miyamoto K, Nakano Y, et al. (2008) Role of interleukin-6 in bleomycin-induced lung inflammatory changes in mice. Am J Respir Cell Mol Biol 38: 566-571.
22. Hirano T, Kishimoto T, (1992) Molecular biology and immunology of interleukin-6. Res Immunol 143: 723-724.
23. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L, (1998) Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 334 (Pt 2): 297-314.
24. Fielding CA, McLoughlin RM, McLeod L, Colmont CS, Najdovska M, et al. (2008) IL-6 regulates neutrophil trafficking during acute inflammation via STAT3. J Immunol 181: 2189-2195.
25. Ikegami M, Falcone A, Whitsett JA, (2008) STAT-3 regulates surfactant phospholipid homeostasis in normal lung and during endotoxin-mediated lung injury. J Appl Physiol 104: 1753-1760. Epub 2008 Mar 1727.
26. Yu H, Pardoll D, Jove R, (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9: 798-809.
27. Blackburn MR, Volmer JB, Thrasher JL, Zhong H, Crosby JR, et al. (2000) Metabolic consequences of adenosine deaminase deficiency in mice are associated with defects in alveogenesis, pulmonary inflammation, and airway obstruction. J Exp Med 192: 159-170.
28. Chunn JL, Molina JG, Mi T, Xia Y, Kellems RE, et al. (2005) Adenosine-dependent pulmonary fibrosis in adenosine deaminase-deficient mice. J Immunol 175: 1937-1946.
29. Blackburn MR, Datta SK, Kellems RE, (1998) Adenosine deaminase-deficient mice generated using a two-stage genetic engineering strategy exhibit a combined immunodeficiency. J Biol Chem 273: 5093-5100.
30. Young HW, Molina JG, Dimina D, Zhong H, Jacobson M, et al. (2004) A3 adenosine receptor signaling contributes to airway inflammation and mucus production in adenosine deaminase-deficient mice. J Immunol 173: 1380-1389.
31. Zhou Y, Mohsenin A, Morschl E, Young HW, Molina JG, et al. (2009) Enhanced airway inflammation and remodeling in adenosine deaminase-deficient mice lacking the A2B adenosine receptor. J Immunol 182: 8037-8046.
32. Ashcroft T, Simpson JM, Timbrell V, (1988) Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol 41: 467-470.
33. Mohsenin A, Burdick MD, Molina JG, Keane MP, Blackburn MR, (2007) Enhanced CXCL1 production and angiogenesis in adenosine-mediated lung disease. Faseb J 21: 1026-1036.
34. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
35. Ding C, Cicuttini F, Li J, Jones G, (2009) Targeting IL-6 in the treatment of inflammatory and autoimmune diseases. Expert Opin Investig Drugs 18: 1457-1466.
36. Eckle T, Faigle M, Grenz A, Laucher S, Thompson LF, et al. (2008) A2B adenosine receptor dampens hypoxia-induced vascular leak. Blood 111: 2024-2035.
37. Zhou Y, Schneider DJ, Morschl E, Song L, Pedroza M, et al. Distinct roles for the A2B adenosine receptor in acute and chronic stages of bleomycin-induced lung injury. J Immunol 186: 1097-1106.
38. Schingnitz U, Hartmann K, Macmanus CF, Eckle T, Zug S, et al. Signaling through the A2B adenosine receptor dampens endotoxin-induced acute lung injury. J Immunol 184: 5271-5279.
39. Eckle T, Grenz A, Laucher S, Eltzschig HK, (2008) A2B adenosine receptor signaling attenuates acute lung injury by enhancing alveolar fluid clearance in mice. J Clin Invest 118: 3301-3315.
40. Belikoff BG, Hatfield S, Georgiev P, Ohta A, Lukashev D, et al. TNF and IL-6 mediate MIP-1alpha expression in bleomycin-induced lung injury. J Leukoc Biol 64: 2444-2453.
41. Smith RE, Strieter RM, Phan SH, Lukacs N, Kunkel SL, (1998) TNF and IL-6 mediate MIP-1alpha expression in bleomycin-induced lung injury. J Leukoc Biol 64: 528-536.
42. Jones SA, (2005) Directing transition from innate to acquired immunity: defining a role for IL-6. J Immunol 175: 3463-3468.
43. Schneider DJ, Lindsay JC, Zhou Y, Molina JG, Blackburn MR, (2009) Adenosine and osteopontin contribute to the development of chronic obstructive pulmonary disease. Faseb J.
44. Korn T, Mitsdoerffer M, Croxford AL, Awasthi A, Dardalhon VA, et al. (2008) IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells. Proc Natl Acad Sci U S A 105: 18460-18465 Epub 12008 Nov 18417.
45. Senior RM, Shapiro SD, (1998) Chronic obstructive pulmonary disease: Epidemiology, pathophysiology, and pathogenesis. In: Fishman AP, Elias JA, Fishman JA, Grippi MA, Kaiser LR et al, editors. Fishman's Pulmonary Diseases and Disorders New York, NY McGraw-Hill, Inc pp. 659-681.
46. Shapiro SD, (1999) The macrophage in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 160: S29-32.
47. Knight DA, Ernst M, Anderson GP, Moodley YP, Mutsaers SE, (2003) The role of gp130/IL-6 cytokines in the development of pulmonary fibrosis: critical determinants of disease susceptibility and progression? Pharmacol Ther 99: 327-338.
48. Konno S, Gonokami Y, Kurokawa M, Kawazu K, Asano K, et al. (1996) Cytokine concentrations in sputum of asthmatic patients. Int Arch Allergy Immunol 109: 73-78.
49. Donaldson GC, Seemungal TA, Patel IS, Bhowmik A, Wilkinson TM, et al. (2005) Airway and systemic inflammation and decline in lung function in patients with COPD. Chest 128: 1995-2004.
50. Moodley YP, Scaffidi AK, Misso NL, Keerthisingam C, McAnulty RJ, et al. (2003) Fibroblasts isolated from normal lungs and those with idiopathic pulmonary fibrosis differ in interleukin-6/gp130-mediated cell signaling and proliferation. Am J Pathol 163: 345-354.
51. Hasegawa M, Sato S, Ihn H, Takehara K, (1999) Enhanced production of interleukin-6 (IL-6), oncostatin M and soluble IL-6 receptor by cultured peripheral blood mononuclear cells from patients with systemic sclerosis. Rheumatology (Oxford) 38: 612-617.
52. Chaouat A, Savale L, Chouaid C, Tu L, Sztrymf B, et al. (2009) Role for interleukin-6 in COPD-related pulmonary hypertension. Chest 136: 678-687.
53. Kusano K, Miyaura C, Inada M, Tamura T, Ito A, et al. (1998) Regulation of matrix metalloproteinases (MMP-2,-3,-9, and-13) by interleukin-1 and interleukin-6 in mouse calvaria: association of MMP induction with bone resorption. Endocrinology 139: 1338-1345.
54. Mihara M, Moriya Y, Kishimoto T, Ohsugi Y, (1995) Interleukin-6 (IL-6) induces the proliferation of synovial fibroblastic cells in the presence of soluble IL-6 receptor. Br J Rheumatol 34: 321-325.
55. Hokuto I, Ikegami M, Yoshida M, Takeda K, Akira S, et al. (2004) Stat-3 is required for pulmonary homeostasis during hyperoxia. J Clin Invest 113: 28-37.
56. Matsuzaki Y, Xu Y, Ikegami M, Besnard V, Park KS, et al. (2006) Stat3 is required for cytoprotection of the respiratory epithelium during adenoviral infection. J Immunol 177: 527-537.
57. Matsuzaki Y, Besnard V, Clark JC, Xu Y, Wert SE, et al. (2008) STAT3 regulates ABCA3 expression and influences lamellar body formation in alveolar type II cells. Am J Respir Cell Mol Biol 38: 551-558 Epub 2007 Dec 2020.
58. Matsumoto S, Hara T, Mitsuyama K, Yamamoto M, Tsuruta O, et al. (1543) Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model. J Immunol 184: 1543-1551.
59. Volmer JB, Thompson LF, Blackburn MR, (2006) Ecto-5′-nucleotidase (CD73)-mediated adenosine production is tissue protective in a model of bleomycin-induced lung injury. J Immunol 176: 4449-4458.